期刊文献+

雌二醇透皮喷雾成膜剂的研制及其体外评价 被引量:7

Development and in vitro evaluation of estradiol transdermal film-forming spray
原文传递
导出
摘要 为了开发雌二醇的透皮喷雾成膜剂,以溶液外观、喷雾性能、成膜速度和外观为指标,筛选了适于制备透皮喷雾成膜剂的聚合物。以乳猪皮肤为模型,考察了聚合物、增塑剂和促渗剂对药物透皮速率的影响,并与商品化的雌二醇贴剂和凝胶比较。使用差示扫描量热法(DSC)考察药物在相变型透皮喷雾剂所成膜中的存在状态。Eudragit E PO、RL PO、羟丙基纤维素EF、聚乙烯吡咯酮K30、Plasdone S630、Agrimer VA64的溶液外观、喷雾性能、成膜速度和外观均符合要求,可以用于制备透皮喷雾成膜剂。雌二醇在以Eudragit RL PO制备的制剂中透皮速率最高;增塑剂柠檬酸三乙酯使透皮速率降低;促渗剂油酸、肉豆蔻酸异丙酯和薄荷醇使雌二醇的透皮速率降低,月桂氮酮使雌二醇的透皮速率增加。透皮喷雾成膜剂的透皮速率和24 h累积透过量均高于贴剂和凝胶。DSC结果表明雌二醇以分子的形式存在于透皮喷雾成膜剂给药后所形成的薄膜中。提示透皮喷雾成膜剂有望成为高效的透皮制剂。 To develop estradiol transdermal film-forming spray (TFS), various polymers were screened using solvent appearance, spray ability, film-forming rate and appearance as indices. The influence of polymer type, plasticizer and penetration enhancer on the transdermal flux were investigated by selecting porcine skin as model, and transdermal flux of TFS was compared with commercial patch and gel. The drug existing state in the formed film was investigated by differential scanning calorimetry (DSC). The solvent appearances, spray abilities, film-forming rates and appearances of eudragit E PO, RL PO, hydroxypropyl cellulose EF, polyvinylpyrrolidone K30, Plasdone $630 and Agrimer VA64 were suitable for the preparation of TFS. TFS prepared by Eudragit RL PO had the biggest transdermal flux of estradiol among all the polymers investigated. Triethyl citrate, the plasticizer, decreased the transdermal flux. Azone increased the transdermal flux, while oleic acid, isopropyl myristate and menthol had opposite effects. TFS had a higher transdermal rate and a higher accumulative penetrated estradiol of 24 h than commercial patch and gel. The DSC result showed that estradiol was spread as molecule in the formed film of TFS. It was indicated that TFS could be expected to be an effective transdermal drug delivery system.
出处 《药学学报》 CAS CSCD 北大核心 2013年第5期746-751,共6页 Acta Pharmaceutica Sinica
关键词 雌二醇 透皮 差示扫描量热法 月桂氮酮 estradiol transdermal differential scanning calorimetry azone
  • 相关文献

参考文献13

  • 1Genazzani AR, Gambacciani M. HRT in the third millennium [J]. Maturitas, 2001, 38: S49-S55.
  • 2O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products [J]. J Clin Pharmacol, 1995, 35: S18-S24.
  • 3Obach RS, Lombardo F, Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds [J]. Drug Metab Dispos, 2008, 36: 1385-1405.
  • 4Lievertz RW. Pharmacology and pharmacokinetics of estrogens [J]. Am J Obstet Gynecol, 1987, 156: 1289-1293.
  • 5Zheng CX, Liang WQ. Current situation of vaginal drug delivery system [J]. 中国现代应用药学, 2002, 19: 465-469.
  • 6Archer DF. Percutaneous 17 beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women [J]. Menopause, 2003, 10: 516-521.
  • 7O'Connell K, Burkman RT. The transdermal contraceptive patch: an updated review of the literature [J]. Clin Obstet Gynecol, 2007, 50:918-926.
  • 8Meshalkin YP, Artyukhov VY, Pomogaev VA. Optical properties of two types of sex hormones of the cyclopentenephenanthrene series [J]. Opt Spectrosc, 2003, 95: 377-380.
  • 9Jenquin MR, McGinity JW. Characterization of acrylic resin matrix films and mechanisms of drug-polymer interactions [J]. Int J Pharm, 1994, 101: 23-34.
  • 10Moser K, Kriwet K, Kalia YN, et al. Enhanced skin permeation of a lipophilic drug using supersaturated formulations [J]. J Control Release, 2001, 73:245-253.

同被引文献94

引证文献7

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部